Saturday, June 21, 2025
21.7
C
Bengaluru
Hot topics
Healthcare is First a Responsibility…
Patient Centricity, the most talked, least understood and poorly implemented strategy in our domain, if holistically approached and sincerely implemented, can truly transform and lead us towards a culture of ‘Healthcare is a Responsibility’. If every person in the life sciences organization at every level, is motivated, trained and equipped to understand, what is of value to the Patient and then strive towards co-creating, creating or contributing, we can travel a huge distance. Is this ‘Value’ paradigm implementable? Well, some are already doing it...
Digital Marketing Kick Starter for Pharma Marketers
An interview with Salil Kallianpur - Executive VP at GSK Primary Care on the state of digital in pharma marketing and pointers for digital marketing success.
National Seminar on UCPMP
The seminar will help companies especially Product Management Teams and Sales Teams to understand their changing roles due to UCPMP. It will also bring clarity on strategies and promotional inputs including CME's, sampling, gifts etc.
Legal Scrutiny
The October 2016 Issue of MedicinMan features articles by K. Hariram, Vivek Hattangadi, Anup Soans and has a special focus on ethics and morals in the healthcare profession. Other topics covered include new product launches, the role of emotions in pharma sales and sales coaching.
IMS Health Market Reflection Report for September 2016
The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Hot topics
Healthcare Marketing in the Covid-19 Era
How should healthcare business leaders (pharma, devices, diagnostics, disposables...
Doctors Still Considered Noble
The July 2016 issue of MedicinMan with articles by Piyush Agarwal, K. Hariram, Vivek Hattangadi, Anjali Sharma, Chandan Kumar, RB Balakrishna and Pankaj Mehrotra
Track and Trace: Indian Pharma – Current and Future Applicability
Pharmaceutical companies must contend with challenges from supply chain lapses (theft, diversion, S.O.P. deviations, product recalls, reverse logistics etc.) counterfeiting and stringent regulations. These challenges get compounded when dealing across the states and country business operations, besides that not only impact tangible profits but also the intangible brand credibility. In this context, there is also a credible increase in public awareness about the genuineness of medicine (in particular medicine that require cold chain) and their predictability of clinical outcomes.
Providing visibility and full traceability becomes a paramount importance to both the Industry and the Govt. – A fool proof solution not only brings transparency in the system, but can also be a key differentiator, and undoubtedly can create immense opportunities for a competitive advantage.
Digital in Health – Making Healthcare Patient Centric
Interview with Hanno Wolfram, author of Digital in Health
Anup...
IMS Health Market Reflection Report for September 2016
The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
Newsletter
Get important news delivered directly to your inbox and stay connected!